Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SCN4A | P35499 | 9/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SCN1A | P35498 | 2/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3650390 | 0.87 | ALDH1A1 (0.42) | CD44CYP3A4TDP1TSHRPIK3CA | |
| SCHEMBL2476981 | 0.80 | TSHR (0.48) | CD44CYP3A4TDP1TSHRPIK3CA | |
| SCHEMBL10073173 | 0.79 | CD44 (0.52) | CD44CYP3A4TDP1TSHRPIK3CA | |
| SCHEMBL27999832 | 0.78 | CD44 (0.43) | CD44CYP3A4TDP1TSHRPIK3CA | |
| SCHEMBL107810 | 0.78 | ALDH1A1 (0.45) | CYP3A4TDP1TSHRALDH1A1USP2 | |
| SCHEMBL24394208 | 0.76 | ALDH1A1 (0.43) | CYP3A4TSHRALDH1A1SCN4AMAOA | |
| SCHEMBL10766684 | 0.76 | TSHR (0.53) | TSHRALDH1A1USP2GAAPKM | |
| SCHEMBL10245323 | 0.76 | ACHE (0.43) | CYP3A4TSHRSCN4AMAOALMNA | |
| SCHEMBL19788218 | 0.76 | KDM4E (0.37) | CYP3A4TSHRALDH1A1GAASCN4A | |
| SCHEMBL11482215 | 0.76 | CXCR5 (0.42) | CD44CYP3A4TDP1TSHRPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548932-B2 | Anti-VEGF protein compositions and methods for producing the same | REGENERON PHARMACEUTICALS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11542317-B1 | Anti-VEGF protein compositions and methods for producing the same | REGENERON PHARMACEUTICALS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220396608-A1 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | REGENERON PHARMACEUTICALS, INC. | 2022-12-15 | — | — | US | disclosed |
| EP-0062200-B1 | DISAZO DYESTUFFS | BASF Aktiengesellschaft (DE) | 1985-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548932-B2 | Anti-VEGF protein compositions and methods for producing the same | VEGFA, HDGF, PDGFA | CD44 617/4885CYP3A4 4826/4885TDP1 3043/4885 |
| US-20220396608-A1 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | VEGFA, HDGF, FLT4 | CD44 344/4885CYP3A4 4821/4885TDP1 3159/4885 |
| US-11542317-B1 | Anti-VEGF protein compositions and methods for producing the same | VEGFA, HDGF, FLT4 | CD44 344/4885CYP3A4 4821/4885TDP1 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.